Interim report January - September 2009
(Thomson Reuters ONE) - * The Group's sales for the period amounted to SEK 481 (412) million* EBITDA amounted to SEK 75 (49) million* EBIT amounted to SEK 58 (39) million* The net profit after tax for the period amounted to SEK 16 (34) million** Earnings per share after tax for the period were SEK 0.05 (0.17 ) before and after dilution*Significant events during the period* The capital acquisition implemented in Q2 is fully subscribed, bringing BioPhausia proceeds ofSEK 64 million before expenses.* Generic product sales are launched in Poland in Q3.* Novalucol is among the limited number of non-prescription drugs cleared for sale in the largesupermarket chains.* Employees acquired 2,334,000 warrants in Q3 under the new incentive programme.Period July-September* The Group's sales for the quarter amounted to SEK 148 (159) million* EBITDA amounted to SEK 21 (26) million* Operating profit was SEK 15 (21) million* Profit after tax amounted to SEK 1 (2) million* Earnings per share after tax was SEK 0.00 (0.01) before and after dilutionStockholm 20 of November 2009CLAES THULINCHIEF EXECUTIVE OFFICERFOR FURTHER INFORMATIONClaes Thulin CEO, +46-8-407 64 30www.biophausia.sehttp://hugin.info/130049/R/1356615/329671.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 23.11.2009 - 12:54 Uhr
Sprache: Deutsch
News-ID 8737
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 270 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Interim report January - September 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
BioPhausia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
